Ken Griffin Arca Biopharma, Inc. Put Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$1.71 - $4.0 $9,576 - $22,400	5,600 New	5,600 $21,000
Q3 2023 Nov 14, 2023	BUY	$2.01 - $2.07 $200 - $206	100 New	100 $0
Q1 2023 May 15, 2023	BUY	$1.99 - $2.55 $7,761 - $9,945	3,900 Added 114.71%	7,300 $14,000
Q4 2022 Feb 14, 2023	SELL	$1.86 - $25.8 $25,110 - $348,300	-13,500 Reduced 79.88%	3,400 $8,000
Q3 2022 Nov 14, 2022	SELL	$2.13 - $25.68 $70,716 - $852,576	-33,200 Reduced 66.27%	16,900 $35,000

12.9M

41.6K

5.6K

Ticker ABIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,410,100
Description
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.